Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study

Am J Hematol. 2020 Sep;95(9):E235-E238. doi: 10.1002/ajh.25864. Epub 2020 Jun 20.

Authors

Xin-Xin Cao¹, Jian Li¹, Ai-Lin Zhao¹, Tian-Hua He¹, Xue-Min Gao¹, Hua-Cong Cai¹, Lu Zhang¹, Yan Zhang¹, Jun Feng¹, Tie-Nan Zhu¹, Na Niu², Jian Sun³, Zhi-Yong Liang³, Ming-Hui Duan¹, Dao-Bin Zhou¹

Affiliations

¹ Department of Hematology, Peking Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Union Medical College, Beijing, China.
² Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
³ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

PMID: 32395858
DOI: 10.1002/ajh.25864

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Cytarabine / administration & dosage*
Cytarabine / adverse effects
Disease-Free Survival
Drug Therapy, Combination
Female
Histiocytosis, Langerhans-Cell* / diagnosis
Histiocytosis, Langerhans-Cell* / drug therapy
Histiocytosis, Langerhans-Cell* / mortality
Humans
Male
Methotrexate / administration & dosage*
Methotrexate / adverse effects
Middle Aged
Prospective Studies
Survival Rate

Substances

Cytarabine
Methotrexate